Wu Yingying, Liu Jingdi, Zeng Wei, Hu Bei, Hu Yu, Tang Liang V
Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Front Cardiovasc Med. 2022 Jun 23;8:796755. doi: 10.3389/fcvm.2021.796755. eCollection 2021.
Plasma levels of the anticoagulant cofactor protein S and PROS1 mutation are reported to impart increased risk of thromboembolism in European and south east Asian populations, but the relationship is not yet documented in Han Chinese in population-based study. Therefore, we undertook a case-control study of this relationship among patients with venous thromboembolism, and probed the genetic factors contributing to low protein S deficiency. Among the 603 consecutively recruited venous thromboembolism patients, 51 (8.5%) proved to be deficient in free protein S antigen (lower than 38.6 U/dl), among whom 30 cases were identified to have a causative mutation by direct sequencing. In contrast, six cases (1.0%) of the 584 healthy controls had low free antigen levels, among whom direct sequencing confirmed disease-causing gene mutations in four controls (0.7%). After adjusting for age and gender, the odds ratio of developing venous thromboembolism in individuals with protein S deficiency based on free protein S tests was 8.1 (95% CI = 3.6-19.9, < 0.001). Gene sequencing yielded 24 different heterozygous mutations in the 34 participants, of which 13 were newly described. 17 (50%) of the 34 mutations in our study cohort occurred in exons 12 and 13, indicating the LGR2 domain to be a hotspot mutation region for the protein. These findings are conducive to the clinical application of protein S assays for the molecular diagnosis of thrombophilia.
据报道,抗凝辅助因子蛋白S的血浆水平和PROS1突变会增加欧洲和东南亚人群发生血栓栓塞的风险,但在基于人群的研究中,汉族人群中的这种关系尚未得到证实。因此,我们对静脉血栓栓塞患者进行了一项关于这种关系的病例对照研究,并探究了导致低蛋白S缺乏的遗传因素。在连续招募的603例静脉血栓栓塞患者中,51例(8.5%)被证明游离蛋白S抗原缺乏(低于38.6 U/dl),其中30例通过直接测序鉴定出有致病突变。相比之下,584例健康对照中有6例(1.0%)游离抗原水平较低,其中4例(0.7%)通过直接测序证实有致病基因突变。在调整年龄和性别后,基于游离蛋白S检测的蛋白S缺乏个体发生静脉血栓栓塞的比值比为8.1(95%可信区间=3.6-19.9,<0.001)。基因测序在34名参与者中产生了24种不同的杂合突变,其中13种是新描述的。在我们的研究队列中,34种突变中有17种(50%)发生在外显子12和13中,表明LGR2结构域是该蛋白的热点突变区域。这些发现有助于蛋白S检测在血栓形成倾向分子诊断中的临床应用。